Joseph Minhow Chan

Joseph Minhow Chan

Auto-generated profile, based on publicly available information

Joseph Minhow Chan

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LPLaura Pasqualucci
Laura Pasqualucci
VTVladimir Trifonov
Vladimir Trifonov
GFGiulia Fabbri
Giulia Fabbri
JMJing Ma
Jing Ma
DRDavide Rossi
Davide Rossi
RDRiccardo Dalla-Favera
Riccardo Dalla-Favera
Laura Pasqualucci and Riccardo Dalla-Favera and colleagues report exome sequencing and copy-number analyses of diffuse large B-cell lymphomas. Their analyses identified mutations in genes not previously implicated in DLBCL pathogenesis, such as genes encoding chromatin modifiers such as MLL2. Diffuse large B-cell lymphoma (DLBCL) is the most common form of human lymphoma. Although a number of structural alterations have been associated with the pathogenesis of this malignancy, the full spectrum of genetic lesions that are present in the DLBCL genome, and therefore the identity of dysregulated cellular pathways, remains unknown. By combining next-generation sequencing and copy number analysis, we show that the DLBCL coding genome contains, on average, more than 30 clonally represented gene alterations per case. This analysis also revealed mutations in genes not previously implicated in DLBCL pathogenesis, including those regulating chromatin methylation (MLL2; 24% of samples) and immune recognition by T cells. These results provide initial data on the complexity of the DLBCL coding genome and identify novel dysregulated pathways underlying its pathogenesis.

7 September 2012 in Science
Verified
Journal Article
Closed access
PDF file
DSDevendra Singh
Devendra Singh
JCJoseph Minhow Chan
Joseph Minhow Chan
PZPietro Zoppoli
Pietro Zoppoli
FNFrancesco Niola
Francesco Niola
RSRyan Sullivan
Ryan Sullivan
AIAntonio Iavarone
Antonio Iavarone
Oncogenic TACC-tics: Human cancers exhibit many types of genomic rearrangements—including some that juxtapose sequences from two unrelated genes—thereby creating fusion proteins with oncogenic activity. Functional analysis of these fusion genes can provide mechanistic insights into tumorigenesis and potentially lead to effective drugs, as famously illustrated by the BCR-ABL gene in chronic myelogenous leukemia. Singh et al. (p. 1231 , published online 26 July) identify and characterize a fusion gene present in 3% of human glioblastomas, a deadly brain cancer. In the resultant fusion protein, the tyrosine kinase region of the fibroblast growth factor receptor (FGFR) is joined to a domain from a transforming acidic coiled-coil (TACC) protein. The TACC-FGFR protein is oncogenic, shows unregulated kinase activity, localizes to the mitotic spindle, and disrupts chromosome segregation. In mice, FGFR inhibitors slowed the growth of tumors driven by the TACC-FGFR gene, suggesting that a subset of glioblastoma patients may benefit from these types of drugs.

16 April 2020 in Cell
Verified
Journal Article
Open access
OROrit Rozenblatt-Rosen
Orit Rozenblatt-Rosen
ARAviv Regev
Aviv Regev
POPhilipp Oberdoerffer
Philipp Oberdoerffer
TNTal Nawy
Tal Nawy
AHAnna Hupalowska
Anna Hupalowska
XZXiaowei Zhuang
Xiaowei Zhuang
Crucial transitions in cancer-including tumor initiation, local expansion, metastasis, and therapeutic resistance-involve complex interactions between cells within the dynamic tumor ecosystem. Transformative single-cell genomics technologies and spatial multiplex in situ methods now provide an opportunity to interrogate this complexity at unprecedented resolution. The Human Tumor Atlas Network (HTAN), part of the National Cancer Institute (NCI) Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types. This effort complements both ongoing efforts to map healthy organs and previous large-scale cancer genomics approaches focused on bulk sequencing at a single point in time. Generating single-cell, multiparametric, longitudinal atlases and integrating them with clinical outcomes should help identify novel predictive biomarkers and features as well as therapeutically relevant cell types, cell states, and cellular interactions across transitions. The resulting tumor atlases should have a profound impact on our understanding of cancer biology and have the potential to improve cancer detection, prevention, and therapeutic discovery for better precision-medicine treatments of cancer patients and those at risk for cancer.

9 March 2020 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ÁQÁlvaro Quintanal-Villalonga
Álvaro Quintanal-Villalonga
JCJoseph M. Chan
Joseph M. Chan
HYHelena A. Yu
Helena A. Yu
DPDana Pe’er
Dana Pe’er
CSCharles L. Sawyers
Charles L. Sawyers
CRCharles M. Rudin
Charles M. Rudin

5 August 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
VFVeronique Frattini
Veronique Frattini
VTVladimir Trifonov
Vladimir Trifonov
JCJoseph Minhow Chan
Joseph Minhow Chan
ACAngelica Castano
Angelica Castano
MLMarie Lia
Marie Lia
AIAntonio Iavarone
Antonio Iavarone
Anna Lasorella, Raul Rabadan, Antonio Iavarone and colleagues report an integrated analysis of genomic alterations in glioblastoma. They identify and functionally validate several new driver events, including loss-of-function mutations in CTNND2 and recurrent EGFR fusions. Glioblastoma is one of the most challenging forms of cancer to treat. Here we describe a computational platform that integrates the analysis of copy number variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma. We found mutations with loss of heterozygosity in LZTR1, encoding an adaptor of CUL3-containing E3 ligase complexes. Mutations and deletions disrupt LZTR1 function, which restrains the self renewal and growth of glioma spheres that retain stem cell features. Loss-of-function mutations in CTNND2 target a neural-specific gene and are associated with the transformation of glioma cells along the very aggressive mesenchymal phenotype. We also report recurrent translocations that fuse the coding sequence of EGFR to several partners, with EGFR-SEPT14 being the most frequent functional gene fusion in human glioblastoma. EGFR-SEPT14 fusions activate STAT3 signaling and confer mitogen independence and sensitivity to EGFR inhibition. These results provide insights into the pathogenesis of glioblastoma and highlight new targets for therapeutic intervention.

14 October 2021 in Cancer Cell
Verified
Journal Article
Open access
JCJoseph M. Chan
Joseph M. Chan
ÁQÁlvaro Quintanal-Villalonga
Álvaro Quintanal-Villalonga
VGVianne Ran Gao
Vianne Ran Gao
YXYubin Xie
Yubin Xie
VAViola Allaj
Viola Allaj
CRCharles M. Rudin
Charles M. Rudin
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 SCLC transcriptomes. We observe greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a PLCG2-high SCLC phenotype with stem-like, pro-metastatic features that recurs across subtypes and predicts worse overall survival. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltrate and greater T-cell dysfunction than SCLC-A. We identify a profibrotic, immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, PLCG2-high subpopulation.